LG 100268

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H29NO2
Molecular Weight	363.4926
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C3(CC3)C4=CC=C(C=N4)C(O)=O

InChI

InChIKey=SLXTWXQUEZSSTJ-UHFFFAOYSA-N

InChI=1S/C24H29NO2/c1-15-12-18-19(23(4,5)9-8-22(18,2)3)13-17(15)24(10-11-24)20-7-6-16(14-25-20)21(26)27/h6-7,12-14H,8-11H2,1-5H3,(H,26,27)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7636877
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10951538 | https://www.ncbi.nlm.nih.gov/pubmed/12374698 | https://www.ncbi.nlm.nih.gov/pubmed/18483313

LG 100268 (LGD 1268) is retionid X receptor agonist, originated in Ligand Pharmaceuticals. LG 100268 demonstrated efficacy in preclinical models of obesity, breast and lung cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Retinoid X receptor 4 Target ID: CHEMBL2363070 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7636877	Agonist 2678		3.0 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Obesity 203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10951538	Primary	Preclinical	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12374698	Primary	Preclinical	Unknown Approved Use Unknown
Lung cancer 69 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18483313	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.	1994 Feb 4	8308867
Activation of specific RXR heterodimers by an antagonist of RXR homodimers.	1996 Oct 3	8837780
Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids.	1999 Nov	10536188
Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.	2005 Dec 15	16357189
Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions.	2005 Oct	15941851
PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver.	2006 May	16489205
In silico prediction of pregnane X receptor activators by machine learning approaches.	2007 Jan	17003167

Patents

Sample Use Guides

In Vivo Use Guide

In obesity studies LG100268 was dosed orally once daily at 20 mg/kg to Zucker rats.

Route of Administration: Oral

In Vitro Use Guide

Receptor binding assays for RXRs were performed using [3H]-9-cis-RA as the radioligand for RXRs. EC50 values we determined by contransfection assay performed with CV-1 cells.

Name

Type

Language

LG 100268

Common Name

English

LG-268

Code

English

AGN-192620

Code

English

6-(1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL)NICOTINIC ACID

Systematic Name

English

LGD 1268

Code

English

3-PYRIDINECARBOXYLIC ACID, 6-(1-(5,6,7,8-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTHALENYL CYCLOPROPYL)-

Common Name

English

CD-3127

Code

English

LGD 100268

Code

English

CD 3127

Code

English

LG100268

Code

English

LG268

Common Name

English

SC-211737

Code

English

LG 268

Code

English

ALRT 268

Code

English

LG-100268

Code

English

LGD-1268

Code

English

AGN 192620

Code

English

ALRT-268

Code

English

LGD-100268

Code

English

Code System Code Type Description

FDA UNII

UVU4X1103P